Dr
Evotec (UK) Ltd, United Kingdom
Dr Adam Stoten is SVP Academic Partnerships at Evotec (UK) Ltd, where he is responsible for creating new international BRIDGE partnerships to accelerate the translation of academic science into new therapeutics. He also serves as Site Head for Evotec’s R&D campus south of Oxford, UK. Prior to Evotec, Dr Stoten was COO and board director at Oxford University Innovation Ltd (OUI), where he was a founding director of spinouts Vaccitech Ltd and EvOx Therapeutics Ltd, and was a co-architect of Evotec's first BRIDGE; LAB282. Between 2010 and 2013 Dr Stoten worked as Deputy General Manager for a spinout company developing a next generation TB vaccine. Prior to this Dr Stoten worked in healthcare consulting and technology transfer roles. Dr Stoten is also a director of PraxisAuril, the UK professional association for knowledge exchange, and ATTP, the body that maintains international standards for the knowledge exchange profession.
Evotec BRIDGEs; pre-seed funding to accelerate academic drug discovery
Wednesday, May 24, 2023
11:30 – 12:00 CET